Pancreatic Cancer Clinical Trials in Cleveland

Showing 81-100 of 142 trials

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

NCT00493441

The study was designed to find the optimum AVN944 dose to use in combination with gemcitabine in patients with pancreatic cancer and see if the combination of the 2 drugs was more effective for treating pancreatic cancer than using gemcitabine alone.

Pancreatic Cancer

Vertex Pharmaceuticals Incorporated28 participantsStarted Jun 2007

Tucson, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +13 more locations

COMPLETEDPhase 3< 1 mile

Immunotherapy Study for Surgically Resected Pancreatic Cancer

NCT01072981

The purpose of this study is to assess overall survival after treatment with a regimen of adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection.

Pancreatic Cancer

NewLink Genetics Corporation722 participantsStarted Apr 2010

Birmingham, Alabama, United States • Mobile, Alabama, United States • Tucson, Arizona, United States +72 more locations

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Pancreatic Cancer Trials in Other Cities

Vaccine Study for Surgically Resected Pancreatic Cancer

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer

Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options

Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery

Other Conditions in Cleveland